Alphamab Oncology
Innovative biopharmaceuticals targeting oncology and autoimmune diseases with advanced antibody therapies
About Alphamab Oncology
Alphamab Oncology is a biopharmaceutical company specializing in the development of innovative antibody therapies for the treatment of oncology and autoimmune diseases. The company focuses on creating multi-functional therapeutic antibodies, which are designed to improve efficacy and safety for patients. Alphamab's core products include KN026, KN035, KN046, and KN019, each targeting different cancer types and immune system disorders. The company primarily serves healthcare providers, hospitals, and research institutions in the global market. Alphamab operates on a business model that includes research and development, clinical trials, and partnerships with other pharmaceutical companies. Revenue is generated through product sales, licensing agreements, and milestone payments from collaborations.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2019
- Outcome tier
- Colt$25–100M revenue
News
Open roles
Alphamab Oncology in the Suzhou Shi ecosystem
The Alphamab Oncology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A8 investors entered at this stage
Heritage Provider Network
Janchor Partners
PAG
OrbiMed- ACAdvantech Capital
- CFChina Ventures Fund
Hudson Bay Capital Management
Adrian Cheng
Series B and later2 investors entered at this stage
- ACAdrian Cheng
- HMHudson Bay Capital Management
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Market sentiment
An AI-synthesised read of the highest-engagement posts about Alphamab Oncology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Alphamab Oncology on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


